The Asia-Pacific Kidney Cancer Diagnostics and Therapeutics Market was worth $0.94 billion in 2018 and estimated to be growing at a CAGR of 5.92%, to reach $1.25 billion by 2023. Kidney cancer is one of the frequent urologic tumours accounting for around 3% of all human cancers.
Surgical methods alone are sometimes not enough for the treatment of these cancers, mainly in cases where patients acquire metastatic cancers. This is when supplementary treatment routines are suggested and various factors such as immunotherapies and targeted therapies come into equation.
The growth of the Asia-Pacific Kidney Cancer Diagnostics and Therapeutics market is mainly due to the rise in aging population, and increasing awareness towards Kidney Cancer. However, poor accessibility of proper care, volatile economies and lack of awareness in this part of the world are the key factors hindering the growth of the market in this region.
The Asia-Pacific Kidney Cancer Diagnostics and Therapeutics market is segmented based on Type and Tests. The market for Kidney Cancer Diagnostics and Therapeutics, on the basis of Type is segmented into Transitional Cell Cancer, Renal cell carcinoma, Renal sarcoma, and Others. On the basis of Tests, the Kidney Cancer Diagnostics and Therapeutics market is segmented into Biopsy, CT Scan, Cystoscopy, Intravenous pyelogram, Kidney Ultrasound. Biopsy and CT Scan lead the tests segment in the Kidney Cancer Diagnostics and Therapeutics market accounting for more than 50% of the market.
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. The Asia-Pacific Kidney Cancer Diagnostics and Therapeutics market is anticipated to increase at the highest CAGR during the forecast period due to reasons such as rising aging population, increasing awareness, and strong economic growth in countries such as China, Japan, and Australia.
The major companies dominating the market in this region are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, Abbott Laboratories.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Cancer
5.1.2 Renal cell carcinoma
5.1.3 Renal sarcoma
5.1.4 Other Cancers
5.2 By Tests
5.2.1 Biopsy
5.2.2 CT Scan
5.2.3 Cystoscopy
5.2.4 Intravenous pyelogram
5.2.5 Kidney Ultrasound
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Bayer
9.3 Pfizer
9.4 Sanofi S.A
9.5 Hoffmann La Roche
9.6 Novartis
9.7 Abbott Laboratories
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
